CPIPS 2020: 5th China Pharma IP Summit, Oct 15-17,Shanghai China

In recent years, China has taken many powerful reform measures to strengthen the protection of intellectual property rights, create a protective environment for innovation in the pharmaceutical industry, accelerate the transformation and upgrading of generic drug companies, balance innovation, competition and prescription drug affordability. According to the “Opinions on Strengthening the Protection of Intellectual Property” Promotion Plan” released by CNIPA on April 20. The Promotion Plan specifically references and appears to be a further implementation of the CPC/State Council Opinion on Strengthening the Protection of Intellectual Property, released in November 2019. It clearly mentioned the establishment of the drug patent linkage system (pre-market notification system) and the patent term compensation system by this Oct 2020.

 
As the second largest pharmaceutical industry in the world and China continue to widen the door for foreign drugmakers to get market access. Meanwhile, Domestic players are also stepping up their activities in overseas country. In this process, it is particularly important for foreign and domestics players to navigate the changing pharma IP and regulatory landscape in China and the rest of the word.

5th China Pharma IP Summit 2020 will once again bring together leading in-house IP counsel, patent prosecutors and litigators, government officials and policy experts from around the world who will share their insights on the latest IP strategies for thriving at a time when regulatory and IP landscape changes are significantly impacting your business models.

This event truly is the largest of its kind to be held in Shanghai China from Oct 15th to 16th , and we will be thrilled to have you join us to reap the benefits of the handpicked, high-level and well-informed presenters, dedicated networking breaks and stimulating interactive sessions taking place over this jam-packed three-day event and Plus few Pre-Conference workshops.

Get Insights to Address:

• The Development of U.S. China Trade Deal/Patent Law Amendment, Implementation Rules and Laws for Patent Linkage and Patent Term Extension
  

• Challenges and Opportunities Under China Ongoing Generics Consistency Evaluation, New IP Landscape for Generics and Innovators

• Patent Examination Standards & Differences and Determination for Patent Infringement in China, EU and US

• Generics and Biosimilars in China, EU and US: IP Landscape, Regulatory Issues, Patent Cliff and Market Entry
  

• Recent Trends and Effect of ANDA Litigation and Biosimilar Litigation in US
  

• Applicable Scope and Comparison of SPC in EU and PTE in US, Lifecycle Management and Patent Portfolio Development 
  

• Patenting Antibodies, Cell & Gene Therapies and Cutting Edge Technologies: Patentable Subject Matter, Special Requirements in Patent Application and Examination Proceedings

• Medical Use Patent Developments: Comparison of Examination and Granting Rules in China, EU and US
  

• Patent Licensing: Considerations, Negotiation, Agreements Drafting and Pitfalls
  

• Pharma&Biotech Patents Examination Practice and §101 Landscape in US

• Biosimilar Going Out : Patent and Regulation Considerations: Challenges and Opportunities
  

• Strategy and Best Practice for International or Foreign Patent Filing

CPIPS 2020 Conference Structure :

Source：iprdaily.com

Editor：Vapor